## Supplementary Table 1. Virological outcomes at weeks 48 and 96

|  | **Week 48** | **Week 96** |
| --- | --- | --- |
|  | **FTC/TAF(n = 333)** | **FTC/TDF(n = 330)** | **FTC/TAF (n = 333)** | **FTC/TDF (n = 330)** |
| Virologic success (HIV‑1 RNA < 50 copies/mL) | 314 (94.3%) | 307 (93.0%) | 295 (88.6%) | 294 (89.1%) |
| Treatment difference | 1.3% (95% CI: ‑2.5% to 5.1%) | ‑0.5% (95% CI: ‑5.3% to 4.4%) |
| Virologic failure | 1 (0.3%) | 5 (1.5%) | 8 (2.4%) | 2 (0.6%) |
| HIV‑1 RNA ≥ 50 copies/mL | 0 | 5 (1.5%) | 5 (1.5%) | 2 (0.6%) |
| Discontinued Study Drug Due to Lack of Efficacy | 0 | 0 | 0 | 0 |
| Discontinued Study Drug Due to Other Reasons and Last Available HIV-1 RNA ≥50 copies/mLc | 1 (0.3%) | 0 | 3 ( 0.9%) | 0 |
| No virologic data at Week 48 or 96 window | 18 (5.4%) | 18 (5.5%) | 30 (9.0%)  | 34 (10.3%) |
| Discontinued study drug due to AE or deathd | 7 (2.1%) | 3 (0.9%) | 8 (2.4%)  | 5 (1.5%) |
| Discontinued study drug due to other reasons and last available HIV‑1 RNA < 50 copies/mLc | 10 (3.0%) | 15 (4.5%) | 22 (6.6%)  | 28 (8.5%) |
| Missing data during window but on study drug | 1 (0.3%) | 0 | 0 | 1 (0.3%) |
| Proportion (%) of patients with HIV‑1 RNA < 50 copies/mL by prior treatment regimen |
| Boosted PIs | 142/155 (91.6%) | 140/151 (92.7%) | 133/155 (85.8%) | 133/151 (88.0%) |
| Other third agents | 172/178 (96.6%) | 167/179 (93.2%) | 162/178 (91.0%) | 161/179 (89.9%) |

PI = protease inhibitor

a Week 48 window was between Day 294 and 377 (inclusive).

b Week 96 window was between Day 630 and 713 (inclusive).

c Discontinuation due to other reasons included subjects who prematurely discontinued study drug due to investigator's discretion, withdrew consent, lost to follow-up, noncompliance with study drug, protocol violation, pregnancy, and study termination by sponsor.

d Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.